Skeletal myogenesis is regulated by a group of transcription factors (MyoD, myogenin, myf5, and myf6) that are "basic helix-loop-helix" proteins that bind to the promoters of muscle-specific genes and promote their expression. We have previously shown that after a mutation of Leu122 to Arg the DNA binding basic domain of MyoD confers c-myc-like functional characteristics to the protein. In this study we used singlestrand conformation polymorphism analysis to determine whether such mutations occur naturally in rhabdomyosarcomas. We have found that the basic domains of all the myogenic factors remain unaltered in rhabdomyosarcomas. Selection against such mutations may be the result of functional redundancy of these myogenic transcription factors. (J. Clin. Invest. 1994. 93:5-9.)
Introduction
MyoD, myogenin, myf5, and myf6 are a group of muscle-specific, "basic helix-loop-helix" (bHLH)' transcription factors that regulate skeletal myogenesis (1) (2) (3) . These proteins bind to the promoters of many muscle-specific genes at sites containing the canonical "E-box" sequence CANNTG. After binding, other domains within these myogenic factors activate transcription of the adjacent gene (4) (5) (6) (7) . Although some differences have been noted in the various properties ofthese factors and in their expression during embryogenesis (8) (9) (10) , each one by itself is fully capable of inducing myogenic differentiation when expressed ectopically in nonmyogenic cells such as fibroblasts ( 11) . This suggests that MyoD, myogenin, myf5, and myf6 are components of a redundant cellular mechanism for ensuring the proper timing and progression of skeletal muscle morphogenesis. This concept has gained support from recent experiments demonstrating that skeletal muscle development in mice lacking functional copies of MyoD or myf5 proceeds relatively normally ( 12, 13) .
DNA binding by the myogenic bHLH proteins requires that they first dimerize. However, such DNA binding by homodimers, while specific, is relatively weak ( 14) . Binding is significantly enhanced by heterodimeric association with the ubiquitously expressed products of the E2A gene product (E 12 and E47) and, indeed, the active transcriptional complexes in myogenic cells appear to consist of such heterodimers ( 14) . In the case of MyoD, for example, each component of the heterodimer is thought to contribute a DNA half-site recognition specificity such that the optimal binding site (CACCTG) is a composite of the preferred binding sites of the individual components in homodimeric form ( 15) . myc family proteins are also members of the bHLH family and bind the E-box motif CACGTG in association with the recently described protein max ( 16, 17) . Myogenic differentiation is accompanied by c-myc downregulation and enforced c-myc expression inhibits the differentiation process ( 18, 19) . The myogenic proteins and c-myccan thus be viewed as components of opposing regulatory pathways in which MyoD and its homologues drive the differentiation process and exert an antiproliferative effect (20) whereas c-myc inhibits myogenic differentiation and drives proliferation (21 ) .
The myogenic and myc family member bHLH proteins contain related DNA binding basic domains (Fig. 1 ) . In particular, MyoD and c-myc are identical at 5 of the 14 amino acids that comprise this motif. Recently, we reported that substitution ofthe myogenically highly conserved Leu, 22 (Fig. 2 ). In all cases tested, DNA fragments containing point mutations were readily distinguishable from the wild-type sequence and from one another after SSCP analysis. We conclude from these experiments that SSCP analysis provides a sensitive and reliable means of detecting point mutation in the MyoD basic domain.
We next analyzed genomic DNA samples obtained from 33 rhabdomyosarcomas ( 19 primary tumors and 14 cell lines) and from the peripheral leukocytes of 10 normal individuals. PCR was performed using primers specific for MyoD, myogenein, myf5, and myf6. Specific amplified bands were obtained in all cases and were subsequently purified by polyacrylamide gel electrophoresis before being subjected to SSCP analysis. The myogenic gene of origin of the amplified fragment was confirmed by establishing the presence of predicted restriction endonuclease sites or by DNA sequencing ofselected cloned fragments (not shown). Under our experimental conditions, the patterns of DNA strand migration were identical for fragments obtained from either normal or tumor DNAs, suggesting identical DNA sequences in the basic domains (Fig. 3) . In the case of myogenin this was confirmed by cloning and sequencing several of the PCR-amplified DNA fragments obtained from tumor DNAs. In all cases, the DNA sequences of the basic rhabdomyosarcomas. We and others have provided evidence that Arg367 ofc-myc is a critical determinant of inner dinucleotide (CG) binding specificity in the c-myc E-box recognition site, CACGTG (35, 36) . This amino acid, highly conserved among myc /max family members, corresponds to the equally well-conserved leucine residue of the four myogenic factors (Leu122 in MyoD), which, by analogy, would be important in the recognition of the CC inner dinucleotide sequence in the MyoD binding site (CACCTG) by the MyoD-E12/E47 heterodimer. Given the importance of these basic domain residues to DNA binding and, in particular, to the profound functional consequences of mutation at these sites (35) , how might we explain why they are not mutated in rhabdomyosarcomas? Perhaps the simplest explanation lies in the redundancy of the myogenic pathway. Assuming that a mutation such as the MyoD Leu122 --Arg did occur, it is quite conceivable that its effects would be negligible due to its competition for binding sites, not only with wild-type MyoD encoded by the unmutated allele but with the other myogenic factors as well. Similarly, despite the progressive decline ofc-myc protein levels in differentiating cells, c-myc binding sites might continue to be occupied by max homodimers that bind with quite high affinity to these sites (37, 38) . Other bHLH proteins, such as the upstream stimulatory factor (39) , and other more recently described max dimerization partners, such as mad and mxi (40, 41 (43) . The second factor that might select against the generation of activating mutations is the nature of the transactivating domains of the myogenic proteins themselves. Although the MyoD Leu122-* Arg mutation does indeed mimic c-myc in terms of its ability to regulate a c-mycresponsive gene, this effect is unlikely to be universal. Other accessory proteins that interact specifically with the c-myc transactivation domain may be essential for the proper regulation of target genes involved in the transformation pathway. Mutant myogenic proteins with the capacity to bind c-myc sites might not necessarily interact with the accessory factors required for subsequent transcriptional control ofall c-myc regulated genes. Consistent with this notion is the inability of the mutant MyoD protein to transform susceptible rat embryo cells in conjunction with an activated ras oncogene (our unpublished observations).
In summary, we have demonstrated that mutations in the DNA binding domains of four myogenic proteins do not occur with any appreciable frequency in rhabdomyosarcomas. Such mutations may be selected against as a result ofthe redundancy of the myogenic and c-myc pathways, an intracellular environment that prevents the proper function of the transcriptional activation domains of the myogenic proteins, or lack of binding of accessory proteins necessary for the proper regulation of c-myc-responsive genes.
